Yanshuo Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yanshuo Cao has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Lin Shen
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China
9 shared publications - Chang Liu
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beijing, China
6 shared publications - Changsong Qi
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beijing 100142, China
6 shared publications - Jiajia Yuan
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China
6 shared publications - Jian Li
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China
6 shared publications - Xiaotian Zhang
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China
6 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1-8 from Allogeneic B7-H3–Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study
Supplementary Figure 1 Specificity profiling of the anti-B7-H3 scFv using the Membrane Proteome Array (MPA). Supplementary Figure 2 Study Dose-Escalation Schema. Supplementary Figure 3 Association of Peak CAR-T Cell Expansion (Cmax) with Clinical Outcomes. Supplementary Figure 4 Lymphocyte Reconstitution Dynamics Following UTAA06 Infusion. Supplementary Figure 5 Longitudinal Serum Cytokine Dynamics Following UTAA06 Infusion. Supplementary Figure 6 Association of Cytokine Fold-Change with Clinical Outcomes. Supplementary Figure 7 Host CD8+ Activation and CAR-T Copy Number Kinetics for Individual Patients. Supplementary Figure 8 Longitudinal analysis of NK cell activation and inhibitory markers in patient P10.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1-8 from Allogeneic B7-H3–Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study
Supplementary Figure 1 Specificity profiling of the anti-B7-H3 scFv using the Membrane Proteome Array (MPA). Supplementary Figure 2 Study Dose-Escalation Schema. Supplementary Figure 3 Association of Peak CAR-T Cell Expansion (Cmax) with Clinical Outcomes. Supplementary Figure 4 Lymphocyte Reconstitution Dynamics Following UTAA06 Infusion. Supplementary Figure 5 Longitudinal Serum Cytokine Dynamics Following UTAA06 Infusion. Supplementary Figure 6 Association of Cytokine Fold-Change with Clinical Outcomes. Supplementary Figure 7 Host CD8+ Activation and CAR-T Copy Number Kinetics for Individual Patients. Supplementary Figure 8 Longitudinal analysis of NK cell activation and inhibitory markers in patient P10.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1-5 from Allogeneic B7-H3–Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study
Supplementary Table 1 Final Product Release Criteria for UTAA06 Supplementary Table 2 Representativeness of Study Participants Supplementary Table 3 Baseline Characteristics and Clinical Outcomes of Individual Patients Supplementary Table 4 Characteristics of UTAA06 Products Supplementary Table 5 Serum Tumor Marker Kinetics
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1-5 from Allogeneic B7-H3–Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study
Supplementary Table 1 Final Product Release Criteria for UTAA06 Supplementary Table 2 Representativeness of Study Participants Supplementary Table 3 Baseline Characteristics and Clinical Outcomes of Individual Patients Supplementary Table 4 Characteristics of UTAA06 Products Supplementary Table 5 Serum Tumor Marker Kinetics
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Allogeneic B7-H3–Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study
Purpose:The aim of the study was to evaluate the safety, pharmacokinetics, and preliminary clinical activity of UTAA06, an “off-the-shelf” allogeneic B7-H3–targeted chimeric antigen receptor (CAR) Vδ1T-cell therapy, in patients with pretreated, advanced B7-H3–positive solid tumors.Patients and Methods:In this first-in-human, phase I, dose-escalation study (NCT06372236), 10 patients with advanced solid tumors (including gastric, colorectal, hepatocellular, ovarian, and neuroendocrine cancers) were enrolled. Following lymphodepletion chemotherapy (cyclophosphamide and fludarabine), patients received UTAA06 infusion across three dose levels (5 × 108, 8 × 108, or 1 × 109 cells). The primary endpoint was safety. Secondary endpoints included pharmacokinetics and antitumor efficacy.Results:UTAA06 demonstrated a manageable safety profile; no GVHD was observed, and cytokine release syndrome was limited to two transient grade 1 events. A single dose-limiting toxicity (grade 3 pneumonitis) was reported in one patient at the 5 × 108 cell dose level. Although UTAA06 demonstrated signals of biological activity, including transient reductions in serum tumor markers in 50% of patients, no objective response by RECIST v1.1 criteria was observed. Further analysis identified that the limited CAR T-cell persistence was likely driven by subclinical host-versus-graft rejection.Conclusions:This study provides clinical proof of concept for allogeneic B7-H3–targeted CAR-Vδ1T cells as a safe platform with low risk of GVHD and demonstrable biological activity in solid tumors. However, clinical efficacy was constrained by limited cellular persistence caused by host immune rejection. Future strategies are required to enhance the durability and therapeutic potential of this allogeneic approach.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Allogeneic B7-H3–Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study
Purpose:The aim of the study was to evaluate the safety, pharmacokinetics, and preliminary clinical activity of UTAA06, an “off-the-shelf” allogeneic B7-H3–targeted chimeric antigen receptor (CAR) Vδ1T-cell therapy, in patients with pretreated, advanced B7-H3–positive solid tumors.Patients and Methods:In this first-in-human, phase I, dose-escalation study (NCT06372236), 10 patients with advanced solid tumors (including gastric, colorectal, hepatocellular, ovarian, and neuroendocrine cancers) were enrolled. Following lymphodepletion chemotherapy (cyclophosphamide and fludarabine), patients received UTAA06 infusion across three dose levels (5 × 108, 8 × 108, or 1 × 109 cells). The primary endpoint was safety. Secondary endpoints included pharmacokinetics and antitumor efficacy.Results:UTAA06 demonstrated a manageable safety profile; no GVHD was observed, and cytokine release syndrome was limited to two transient grade 1 events. A single dose-limiting toxicity (grade 3 pneumonitis) was reported in one patient at the 5 × 108 cell dose level. Although UTAA06 demonstrated signals of biological activity, including transient reductions in serum tumor markers in 50% of patients, no objective response by RECIST v1.1 criteria was observed. Further analysis identified that the limited CAR T-cell persistence was likely driven by subclinical host-versus-graft rejection.Conclusions:This study provides clinical proof of concept for allogeneic B7-H3–targeted CAR-Vδ1T cells as a safe platform with low risk of GVHD and demonstrable biological activity in solid tumors. However, clinical efficacy was constrained by limited cellular persistence caused by host immune rejection. Future strategies are required to enhance the durability and therapeutic potential of this allogeneic approach.
- 4 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (10) , 2026-2035
Allogeneic B7-H3–Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study
Purpose: The aim of the study was to evaluate the safety, pharmacokinetics, and preliminary clinical activity of UTAA06, an “off-the-shelf” allogeneic B7-H3–targeted chimeric antigen receptor (CAR) Vδ1T-cell therapy, in patients with pretreated, advanced B7-H3–positive solid tumors. Patients and Methods: In this first-in-human, phase I, dose-escalation study (NCT06372236), 10 patients with advanced solid tumors (including gastric, colorectal, hepatocellular, ovarian, and neuroendocrine cancers) were enrolled. Following lymphodepletion chemotherapy (cyclophosphamide and fludarabine), patients received UTAA06 infusion across three dose levels (5 × 108, 8 × 108, or 1 × 109 cells). The primary endpoint was safety. Secondary endpoints included pharmacokinetics and antitumor efficacy. Results: UTAA06 demonstrated a manageable safety profile; no GVHD was observed, and cytokine release syndrome was limited to two transient grade 1 events. A single dose-limiting toxicity (grade 3 pneumonitis) was reported in one patient at the 5 × 108 cell dose level. Although UTAA06 demonstrated signals of biological activity, including transient reductions in serum tumor markers in 50% of patients, no objective response by RECIST v1.1 criteria was observed. Further analysis identified that the limited CAR T-cell persistence was likely driven by subclinical host-versus-graft rejection. Conclusions: This study provides clinical proof of concept for allogeneic B7-H3–targeted CAR-Vδ1T cells as a safe platform with low risk of GVHD and demonstrable biological activity in solid tumors. However, clinical efficacy was constrained by limited cellular persistence caused by host immune rejection. Future strategies are required to enhance the durability and therapeutic potential of this allogeneic approach.
- 4 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (10) , 2026-2035
Allogeneic B7-H3–Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study
Purpose: The aim of the study was to evaluate the safety, pharmacokinetics, and preliminary clinical activity of UTAA06, an “off-the-shelf” allogeneic B7-H3–targeted chimeric antigen receptor (CAR) Vδ1T-cell therapy, in patients with pretreated, advanced B7-H3–positive solid tumors. Patients and Methods: In this first-in-human, phase I, dose-escalation study (NCT06372236), 10 patients with advanced solid tumors (including gastric, colorectal, hepatocellular, ovarian, and neuroendocrine cancers) were enrolled. Following lymphodepletion chemotherapy (cyclophosphamide and fludarabine), patients received UTAA06 infusion across three dose levels (5 × 108, 8 × 108, or 1 × 109 cells). The primary endpoint was safety. Secondary endpoints included pharmacokinetics and antitumor efficacy. Results: UTAA06 demonstrated a manageable safety profile; no GVHD was observed, and cytokine release syndrome was limited to two transient grade 1 events. A single dose-limiting toxicity (grade 3 pneumonitis) was reported in one patient at the 5 × 108 cell dose level. Although UTAA06 demonstrated signals of biological activity, including transient reductions in serum tumor markers in 50% of patients, no objective response by RECIST v1.1 criteria was observed. Further analysis identified that the limited CAR T-cell persistence was likely driven by subclinical host-versus-graft rejection. Conclusions: This study provides clinical proof of concept for allogeneic B7-H3–targeted CAR-Vδ1T cells as a safe platform with low risk of GVHD and demonstrable biological activity in solid tumors. However, clinical efficacy was constrained by limited cellular persistence caused by host immune rejection. Future strategies are required to enhance the durability and therapeutic potential of this allogeneic approach.
- Open Access
- 10 July 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (10) , 3485-3491
A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial
Research on patients with advanced esophageal squamous cell carcinoma (ESCC) who have progressed on immunotherapy remains limited. BL-B01D1 is a first-in-class antibody–drug conjugate consisting of an EGFR–HER3 bispecific antibody bound to a topoisomerase I inhibitor (Ed-04) payload via a cleavable linker. Here, we present safety and efficacy data from a phase 1 study of BL-B01D1, in 82 patients previously treated for ESCC. The primary endpoint was the recommended phase 2 dose. Administered doses were 2.0 (n = 22) and 2.5 (n = 60) mg kg−1 D1D8 infusion every 3 weeks (Q3W). The confirmed objective response rate (cORR) was 29.3% (24 of 82) in all patients and 32.9% (24 of 73) among evaluable patients. For patients dosed at 2.5 mg kg−1, cORR was 39.6% (21 of 53) and disease control rate was 79.2% (42 of 53). In the 2.0 mg kg−1 group, cORR was 15.0% (3 of 20), and the disease control rate was 50.0% (10 of 20). The phase 2 dose was established at 2.5 mg kg−1 D1D8 Q3W. The incidence of G3 treatment-related adverse events at 2.5 mg kg−1 was 63.3%; most common adverse events were anemia (28.3%), leukopenia and thrombocytopenia (18.3%, each), and neutropenia (16.7%). Two cases of ≥G3 interstitial lung disease were observed. Overall, BL-B01D1 demonstrated promising efficacy and manageable safety in patients with metastatic ESCC. A further phase 3 clinical trial has already been initiated. ClinicalTrials.gov registration: NCT05262491.
- 10 July 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (10) , 3485-3491
Open AccessA bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial
Research on patients with advanced esophageal squamous cell carcinoma (ESCC) who have progressed on immunotherapy remains limited. BL-B01D1 is a first-in-class antibody–drug conjugate consisting of an EGFR–HER3 bispecific antibody bound to a topoisomerase I inhibitor (Ed-04) payload via a cleavable linker. Here, we present safety and efficacy data from a phase 1 study of BL-B01D1, in 82 patients previously treated for ESCC. The primary endpoint was the recommended phase 2 dose. Administered doses were 2.0 (n = 22) and 2.5 (n = 60) mg kg−1 D1D8 infusion every 3 weeks (Q3W). The confirmed objective response rate (cORR) was 29.3% (24 of 82) in all patients and 32.9% (24 of 73) among evaluable patients. For patients dosed at 2.5 mg kg−1, cORR was 39.6% (21 of 53) and disease control rate was 79.2% (42 of 53). In the 2.0 mg kg−1 group, cORR was 15.0% (3 of 20), and the disease control rate was 50.0% (10 of 20). The phase 2 dose was established at 2.5 mg kg−1 D1D8 Q3W. The incidence of G3 treatment-related adverse events at 2.5 mg kg−1 was 63.3%; most common adverse events were anemia (28.3%), leukopenia and thrombocytopenia (18.3%, each), and neutropenia (16.7%). Two cases of ≥G3 interstitial lung disease were observed. Overall, BL-B01D1 demonstrated promising efficacy and manageable safety in patients with metastatic ESCC. A further phase 3 clinical trial has already been initiated. ClinicalTrials.gov registration: NCT05262491.
- 22 May 2025
- Published by Elsevier in Cancer Letters
- Vol. 626, 217792
Harnessing exosomes: From tumor immune escape to therapeutic innovation in gastric cancer immunotherapy
- 22 May 2025
- Published by Elsevier in Cancer Letters
- Vol. 626, 217792
Harnessing exosomes: From tumor immune escape to therapeutic innovation in gastric cancer immunotherapy
- 30 September 2024
- Published by Springer Nature in Investigational New Drugs
- Vol. 42 (6) , 716-727
Gremlin1: a BMP antagonist with therapeutic potential in Oncology
Gremlins, originating from early 20th-century Western folklore, are mythical creatures known for causing mechanical malfunctions and electronic failures, aptly dubbed “little devils”. Analogously, GREM1 acts like a horde of these mischievous entities by antagonizing the bone morphogenetic protein (BMP signaling) pathway or through other non-BMP dependent mechanisms (such as binding to Fibroblast Growth Factor Receptor 1and Epidermal Growth Factor Receptor) contributing to the malignant progression of various cancers. The overexpression of GREM1 promotes tumor cell growth and survival, enhances angiogenesis within the tumor microenvironment, and creates favorable conditions for tumor development and dissemination. Consequently, inhibiting the activity of GREM1 or blocking its interaction with BMP presents a promising strategy for suppressing tumor growth and metastasis. However, the role of GREM1 in cancer remains a subject of debate, with evidence suggesting both oncogenic and tumor-suppressive functions. Currently, several pharmaceutical companies are researching the GREM1 target, with some advancing to Phase I/II clinical trials. This article will provide a detailed overview of the GREM1 target and explore its potential role in cancer therapy.
- 30 September 2024
- Published by Springer Nature in Investigational New Drugs
- Vol. 42 (6) , 716-727
Gremlin1: a BMP antagonist with therapeutic potential in Oncology
Gremlins, originating from early 20th-century Western folklore, are mythical creatures known for causing mechanical malfunctions and electronic failures, aptly dubbed “little devils”. Analogously, GREM1 acts like a horde of these mischievous entities by antagonizing the bone morphogenetic protein (BMP signaling) pathway or through other non-BMP dependent mechanisms (such as binding to Fibroblast Growth Factor Receptor 1and Epidermal Growth Factor Receptor) contributing to the malignant progression of various cancers. The overexpression of GREM1 promotes tumor cell growth and survival, enhances angiogenesis within the tumor microenvironment, and creates favorable conditions for tumor development and dissemination. Consequently, inhibiting the activity of GREM1 or blocking its interaction with BMP presents a promising strategy for suppressing tumor growth and metastasis. However, the role of GREM1 in cancer remains a subject of debate, with evidence suggesting both oncogenic and tumor-suppressive functions. Currently, several pharmaceutical companies are researching the GREM1 target, with some advancing to Phase I/II clinical trials. This article will provide a detailed overview of the GREM1 target and explore its potential role in cancer therapy.
- 12 June 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 137, 112364
Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma
- 12 June 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 137, 112364
Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma
- Top Cited Papers
- 3 June 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (8) , 2224-2234
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Claudin18.2 (CLDN18.2) is highly expressed with the development of various malignant tumors, especially gastrointestinal cancers, and is emerging as a new target for cancer treatment. Satricabtagene autoleucel (satri-cel)/CT041 is an autologous chimeric antigen receptor (CAR) T cell targeting CLDN18.2, and the interim results of the CT041-CG4006 trial were reported in June 2022. Here we present the final results of this single-arm, open-label, phase 1 trial, which evaluated the safety and efficacy of satri-cel in patients with CLDN18.2-positive advanced gastrointestinal cancers. This trial included a dose-escalation stage (n = 15) and a dose-expansion stage in four different cohorts (total n = 83): cohort 1, satri-cel monotherapy in 61 patients with standard chemotherapy-refractory gastrointestinal cancers; cohort 2, satri-cel plus anti-PD-1 therapy in 15 patients with standard chemotherapy-refractory gastrointestinal cancers; cohort 3, satri-cel as sequential treatment after first-line therapy in five patients with gastrointestinal cancers; and cohort 4, satri-cel monotherapy in two patients with anti-CLDN18.2 monoclonal antibody-refractory gastric cancer. The primary endpoint was safety; secondary endpoints included efficacy, pharmacokinetics and immunogenicity. A total of 98 patients received satri-cel infusion, among whom 89 were dosed with 2.5 × 108, six with 3.75 × 108 and three with 5.0 × 108 CAR T cells. Median follow-up was 32.4 months (95% confidence interval (CI): 27.3, 36.5) since apheresis. No dose-limiting toxicities, treatment-related deaths or immune effector cell-associated neurotoxicity syndrome were reported. Cytokine release syndrome occurred in 96.9% of patients, all classified as grade 1–2. Gastric mucosal injuries were identified in eight (8.2%) patients. The overall response rate and disease control rate in all 98 patients were 38.8% and 91.8%, respectively, and the median progression-free survival and overall survival were 4.4 months (95% CI: 3.7, 6.6) and 8.8 months (95% CI: 7.1, 10.2), respectively. Satri-cel demonstrates therapeutic potential with a manageable safety profile in patients with CLDN18.2-positive advanced gastrointestinal cancer. ClinicalTrials.gov identifier: NCT03874897.
- 3 June 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (8) , 2224-2234
Top Cited PapersClaudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Claudin18.2 (CLDN18.2) is highly expressed with the development of various malignant tumors, especially gastrointestinal cancers, and is emerging as a new target for cancer treatment. Satricabtagene autoleucel (satri-cel)/CT041 is an autologous chimeric antigen receptor (CAR) T cell targeting CLDN18.2, and the interim results of the CT041-CG4006 trial were reported in June 2022. Here we present the final results of this single-arm, open-label, phase 1 trial, which evaluated the safety and efficacy of satri-cel in patients with CLDN18.2-positive advanced gastrointestinal cancers. This trial included a dose-escalation stage (n = 15) and a dose-expansion stage in four different cohorts (total n = 83): cohort 1, satri-cel monotherapy in 61 patients with standard chemotherapy-refractory gastrointestinal cancers; cohort 2, satri-cel plus anti-PD-1 therapy in 15 patients with standard chemotherapy-refractory gastrointestinal cancers; cohort 3, satri-cel as sequential treatment after first-line therapy in five patients with gastrointestinal cancers; and cohort 4, satri-cel monotherapy in two patients with anti-CLDN18.2 monoclonal antibody-refractory gastric cancer. The primary endpoint was safety; secondary endpoints included efficacy, pharmacokinetics and immunogenicity. A total of 98 patients received satri-cel infusion, among whom 89 were dosed with 2.5 × 108, six with 3.75 × 108 and three with 5.0 × 108 CAR T cells. Median follow-up was 32.4 months (95% confidence interval (CI): 27.3, 36.5) since apheresis. No dose-limiting toxicities, treatment-related deaths or immune effector cell-associated neurotoxicity syndrome were reported. Cytokine release syndrome occurred in 96.9% of patients, all classified as grade 1–2. Gastric mucosal injuries were identified in eight (8.2%) patients. The overall response rate and disease control rate in all 98 patients were 38.8% and 91.8%, respectively, and the median progression-free survival and overall survival were 4.4 months (95% CI: 3.7, 6.6) and 8.8 months (95% CI: 7.1, 10.2), respectively. Satri-cel demonstrates therapeutic potential with a manageable safety profile in patients with CLDN18.2-positive advanced gastrointestinal cancer. ClinicalTrials.gov identifier: NCT03874897.